Pitchal Balakumar

Summary

Publications

  1. ncbi request reprint Possible role of JAK-2 in attenuated cardioprotective effect of ischemic preconditioning in hyperhomocysteinemic rat hearts
    Gurfateh Singh
    Cardiovascular Pharmacology Division, ISF College of Pharmacy, Punjab, India
    Yakugaku Zasshi 129:523-35. 2009
  2. doi request reprint Effect of rosiglitazone in sodium arsenite-induced experimental vascular endothelial dysfunction
    Tajpreet Kaur
    Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, 147002, India
    Arch Pharm Res 33:611-8. 2010
  3. ncbi request reprint Dapagliflozin: glucuretic action and beyond
    Pitchai Balakumar
    Pharmacology Unit, Faculty of Pharmacy, Asian Institute of Medicine, Science and Technology AIMST University, Semeling, 08100 Bedong, Kedah Darul Aman, Malaysia Electronic address
    Pharmacol Res 82:34-9. 2014
  4. doi request reprint Cardiovascular pleiotropic actions of DPP-4 inhibitors: a step at the cutting edge in understanding their additional therapeutic potentials
    Pitchai Balakumar
    Pharmacology Unit, Faculty of Pharmacy, AIMST University, Semeling, 08100 Bedong, Kedah Darul Aman, Malaysia
    Cell Signal 25:1799-803. 2013
  5. pmc Submaximal PPARγ activation and endothelial dysfunction: new perspectives for the management of cardiovascular disorders
    Pitchai Balakumar
    Cardiovascular Pharmacology Division, Department of Pharmacology, Institute of Pharmacy, Rajendra Institute of Technology and Sciences RITS, Sirsa, India
    Br J Pharmacol 166:1981-92. 2012
  6. doi request reprint Fish oil and vascular endothelial protection: bench to bedside
    Pitchai Balakumar
    Cardiovascular Pharmacology Division, Department of Pharmacology, Institute of Pharmacy, Rajendra Institute of Technology and Sciences, Sirsa 125 055, India
    Free Radic Biol Med 53:271-9. 2012
  7. ncbi request reprint Telmisartan in the management of diabetic nephropathy: a contemporary view
    Pitchai Balakumar
    Department of Pharmacology, Cardiovascular Pharmacology Division, Institute of Pharmacy, Rajendra Institute of Technology and Sciences RITS, Sirsa 125 055, India
    Curr Diabetes Rev 8:183-90. 2012
  8. doi request reprint Are PPAR alpha agonists a rational therapeutic strategy for preventing abnormalities of the diabetic kidney?
    Pitchai Balakumar
    Cardiovascular Pharmacology Division, Department of Pharmacology, Institute of Pharmacy, Rajendra Institute of Technology and Sciences, Sirsa 125055, India
    Pharmacol Res 65:430-6. 2012
  9. doi request reprint Preconditioning the hyperlipidemic myocardium: fact or fantasy?
    Pitchai Balakumar
    Cardiovascular Pharmacology Division, Department of Pharmacology, Institute of Pharmacy, Rajendra Institute of Technology and Sciences RITS, Sirsa, India
    Cell Signal 24:589-95. 2012
  10. doi request reprint Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of statins?
    Pitchai Balakumar
    Cardiovascular Pharmacology Division, Department of Pharmacology, Institute of Pharmacy, Rajendra Institute of Technology and Sciences, Sirsa 125 055, India
    J Mol Cell Cardiol 52:83-92. 2012

Collaborators

Detail Information

Publications44

  1. ncbi request reprint Possible role of JAK-2 in attenuated cardioprotective effect of ischemic preconditioning in hyperhomocysteinemic rat hearts
    Gurfateh Singh
    Cardiovascular Pharmacology Division, ISF College of Pharmacy, Punjab, India
    Yakugaku Zasshi 129:523-35. 2009
    ....
  2. doi request reprint Effect of rosiglitazone in sodium arsenite-induced experimental vascular endothelial dysfunction
    Tajpreet Kaur
    Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, 147002, India
    Arch Pharm Res 33:611-8. 2010
    ..p., 2 weeks). Thus, it may be concluded that rosiglitazone reduces oxidative stress, activates eNOS and enhances the generation of nitric oxide to prevent sodium arsenite-induced VED in rats...
  3. ncbi request reprint Dapagliflozin: glucuretic action and beyond
    Pitchai Balakumar
    Pharmacology Unit, Faculty of Pharmacy, Asian Institute of Medicine, Science and Technology AIMST University, Semeling, 08100 Bedong, Kedah Darul Aman, Malaysia Electronic address
    Pharmacol Res 82:34-9. 2014
    ..Long-term clinical studies are however needed to clarify this contention. ..
  4. doi request reprint Cardiovascular pleiotropic actions of DPP-4 inhibitors: a step at the cutting edge in understanding their additional therapeutic potentials
    Pitchai Balakumar
    Pharmacology Unit, Faculty of Pharmacy, AIMST University, Semeling, 08100 Bedong, Kedah Darul Aman, Malaysia
    Cell Signal 25:1799-803. 2013
    ..This review will shed lights on the newly identified beneficial pleiotropic actions of gliptins on the cardiovascular system. ..
  5. pmc Submaximal PPARγ activation and endothelial dysfunction: new perspectives for the management of cardiovascular disorders
    Pitchai Balakumar
    Cardiovascular Pharmacology Division, Department of Pharmacology, Institute of Pharmacy, Rajendra Institute of Technology and Sciences RITS, Sirsa, India
    Br J Pharmacol 166:1981-92. 2012
    ..Moreover, the therapeutic opportunities of agents that submaximally activate PPARγ in preventing vascular endothelial dysfunction (VED) and VED-associated cardiovascular disorders are discussed...
  6. doi request reprint Fish oil and vascular endothelial protection: bench to bedside
    Pitchai Balakumar
    Cardiovascular Pharmacology Division, Department of Pharmacology, Institute of Pharmacy, Rajendra Institute of Technology and Sciences, Sirsa 125 055, India
    Free Radic Biol Med 53:271-9. 2012
    ..We finally suggest the importance of further studies to determine the dose adjustment of fish oil with an optimal ratio of EPA and DHA for achieving consistent cardiovascular protection...
  7. ncbi request reprint Telmisartan in the management of diabetic nephropathy: a contemporary view
    Pitchai Balakumar
    Department of Pharmacology, Cardiovascular Pharmacology Division, Institute of Pharmacy, Rajendra Institute of Technology and Sciences RITS, Sirsa 125 055, India
    Curr Diabetes Rev 8:183-90. 2012
    ..This review will discuss the current status of therapeutic potentials of telmisartan in treating diabetic nephropathy...
  8. doi request reprint Are PPAR alpha agonists a rational therapeutic strategy for preventing abnormalities of the diabetic kidney?
    Pitchai Balakumar
    Cardiovascular Pharmacology Division, Department of Pharmacology, Institute of Pharmacy, Rajendra Institute of Technology and Sciences, Sirsa 125055, India
    Pharmacol Res 65:430-6. 2012
    ..However, fenofibrate has been shown to cause renal dysfunction in established renal disorders. The present review addressed the rationale of employing PPARα agonists in the management of diabetic nephropathy...
  9. doi request reprint Preconditioning the hyperlipidemic myocardium: fact or fantasy?
    Pitchai Balakumar
    Cardiovascular Pharmacology Division, Department of Pharmacology, Institute of Pharmacy, Rajendra Institute of Technology and Sciences RITS, Sirsa, India
    Cell Signal 24:589-95. 2012
    ..Additionally, novel pharmacologic interventions to attenuate hyperlipidemia-associated exaggerated I/R-induced myocardial injury have been discussed...
  10. doi request reprint Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of statins?
    Pitchai Balakumar
    Cardiovascular Pharmacology Division, Department of Pharmacology, Institute of Pharmacy, Rajendra Institute of Technology and Sciences, Sirsa 125 055, India
    J Mol Cell Cardiol 52:83-92. 2012
    ..The eNOS modulatory role of statins may have an imperative influence on the functional regulation of cardiovascular system and may offer new perspectives for the better use of statins in ameliorating cardiovascular disorders...
  11. doi request reprint Is nicotine a key player or spectator in the induction and progression of cardiovascular disorders?
    Pitchai Balakumar
    Department of Physiology, University of Montreal, Quebec, Canada
    Pharmacol Res 60:361-8. 2009
    ..In addition, the pharmacological interventions to ameliorate chronic nicotine exposure-induced cardiovascular abnormalities have been delineated...
  12. doi request reprint Adenosine-A1 receptors activation restores the suppressed cardioprotective effects of ischemic preconditioning in hyperhomocysteinemic rat hearts
    Pitchai Balakumar
    Cardiovascular Pharmacology Division, ISF College of Pharmacy, Moga, Punjab, India
    J Cardiovasc Pharmacol 54:204-12. 2009
    ..The present study investigated the effect of 2-chloro-N-cyclopentyladenosine (CCPA), a selective adenosine-A1 receptor agonist, in hyperhomocysteinemia-induced attenuation of the cardioprotective effect of IPC...
  13. ncbi request reprint Emerging role of PPAR ligands in the management of diabetic nephropathy
    Pitchai Balakumar
    Cardiovascular Pharmacology Division, ISF College of Pharmacy, Moga 142001, Punjab, India
    Pharmacol Res 60:170-3. 2009
    ..In the present review, we discussed the novel role of PPARalpha and PPARgamma agonists in the management of diabetic nephropathy...
  14. doi request reprint Arsenic exposure and cardiovascular disorders: an overview
    Pitchai Balakumar
    Cardiovascular Pharmacology Division, ISF College of Pharmacy, Moga, Punjab, 142 001, India
    Cardiovasc Toxicol 9:169-76. 2009
    ..The present review critically discussed the detrimental role of arsenic in the cardiovascular system...
  15. doi request reprint The multifaceted therapeutic potential of benfotiamine
    Pitchai Balakumar
    Department of Pharmacology, SB College of Pharmacy, Sivakasi 626130, India
    Pharmacol Res 61:482-8. 2010
    ..Interestingly, few recent studies demonstrated additional non-AGE-dependent pharmacological actions of benfotiamine. The present review critically analyzed the multifaceted therapeutic potential of benfotiamine...
  16. doi request reprint Gentamicin-induced nephrotoxicity: Do we have a promising therapeutic approach to blunt it?
    Pitchai Balakumar
    Department of Pharmacology, SB College of Pharmacy, Sivakasi 626 130, India
    Pharmacol Res 62:179-86. 2010
    ..In addition, based on the experimental and clinical studies, the possible therapeutic approach to prevent gentamicin-induced nephrotoxicity has been discussed...
  17. doi request reprint Multifarious molecular signaling cascades of cardiac hypertrophy: can the muddy waters be cleared?
    Pitchai Balakumar
    Department of Pharmacology, SB College of Pharmacy, Sivakasi 626 130, India
    Pharmacol Res 62:365-83. 2010
    ..Elucidation of signaling cascades that initiate cardiac hypertrophy will open up a new area of research in developing innovative therapeutics for the treatment of pathological cardiac hypertrophy...
  18. doi request reprint Pleiotropic actions of fenofibrate on the heart
    Pitchai Balakumar
    Department of Pharmacology, Institute of Pharmacy, Rajendra Institute of Technology and Sciences, Sirsa 125055, India
    Pharmacol Res 63:8-12. 2011
    ..In this review, we critically discussed recently identified pleiotropic actions of fenofibrate on the heart. Moreover, the novel cardioprotective effects of fenofibrate against various cardiac disorders have been delineated...
  19. pmc Interplay between statins and PPARs in improving cardiovascular outcomes: a double-edged sword?
    Pitchai Balakumar
    Cardiovascular Pharmacology Division, Department of Pharmacology, Institute of Pharmacy, Rajendra Institute of Technology and Sciences, Sirsa, India
    Br J Pharmacol 165:373-9. 2012
    ..The present review addressed the underlying principles pertaining to the modulatory role of statins on PPARs...
  20. doi request reprint Healing the diabetic heart: does myocardial preconditioning work?
    Pitchai Balakumar
    Cardiovascular Pharmacology Division, Department of Pharmacology, Rajendra Institute of Technology and Sciences RITS, Sirsa, India
    Cell Signal 24:53-9. 2012
    ..These are important to be understood for better exploitation of preconditioning strategies in limiting I/R-induced myocardial injury in the diabetic heart...
  21. doi request reprint Pathophysiology of diabetic nephropathy: involvement of multifaceted signalling mechanism
    Pitchai Balakumar
    Department of Physiology, University of Montreal, CP 6128, Succ Centreville, Montreal, QC H3C 3J7, Canada
    J Cardiovasc Pharmacol 54:129-38. 2009
    ..The purpose of this review is to bring together the current information concerning the signalling systems involved in the pathogenesis of diabetic nephropathy...
  22. doi request reprint Pre-conditioning and postconditioning to limit ischemia-reperfusion-induced myocardial injury: what could be the next footstep?
    Pitchai Balakumar
    ISF Institute of Pharmaceutical Sciences and Drug Research, Moga 142001, Punjab, India
    Pharmacol Res 57:403-12. 2008
    ..Moreover, the clinical relevance and factors affecting the cardioprotective potentials of pre- and postconditioning have been delineated...
  23. ncbi request reprint PPAR dual agonists: are they opening Pandora's Box?
    Pitchai Balakumar
    Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, Punjab, India
    Pharmacol Res 56:91-8. 2007
    ....
  24. doi request reprint Potential target sites to modulate vascular endothelial dysfunction: current perspectives and future directions
    Pitchai Balakumar
    I S F Institute of Pharmaceutical Sciences and Drug Research, Moga 142001, Punjab, India
    Toxicology 245:49-64. 2008
    ..The present review delineates various potential target sites for vascular endothelial dysfunction, which may open a new vista for exploring novel pharmacological agents to treat various cardiovascular disorders...
  25. ncbi request reprint Vascular endothelial dysfunction: a tug of war in diabetic nephropathy?
    Pitchai Balakumar
    Cardiovascular Pharmacology Division, ISF College of Pharmacy, Moga 142 001, Punjab, India
    Biomed Pharmacother 63:171-9. 2009
    ..Thus it is suggested that diabetes-induced VED could be one of the culprits involved in the pathogenesis of diabetic nephropathy...
  26. doi request reprint Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat
    Pitchai Balakumar
    Cardiovascular Pharmacology Division, ISF College of Pharmacy, Moga 142 001, India
    Mol Cell Biochem 320:149-62. 2009
    ....
  27. ncbi request reprint Benfotiamine attenuates nicotine and uric acid-induced vascular endothelial dysfunction in the rat
    Pitchai Balakumar
    Cardiovascular Pharmacology Division, ISF College of Pharmacy, Moga 142001, Punjab, India
    Pharmacol Res 58:356-63. 2008
    ....
  28. doi request reprint Experimental models for nephropathy
    Pitchal Balakumar
    Cardiovascular Pharmacology Division, ISF College of Pharmacy, Institute of Pharmaceutical Sciences and Drug Research, Moga, India
    J Renin Angiotensin Aldosterone Syst 9:189-95. 2008
    ..In the present review, we have discussed various animal models for nephropathy, which may open vistas for developing new drugs to treat nephropathy...
  29. doi request reprint The impairment of preconditioning-mediated cardioprotection in pathological conditions
    Pitchai Balakumar
    Department of Physiology, Faculty of Medicine, University of Montreal, Succ Centre Ville, Montreal, Quebec H3C 3J7, Canada
    Pharmacol Res 60:18-23. 2009
    ..In this review, we have critically discussed the possible mechanisms involved in the modulation of cardioprotective potential of ischemic preconditioning in various pathological conditions...
  30. doi request reprint Recent advances in pharmacotherapy for diabetic nephropathy: current perspectives and future directions
    Pitchai Balakumar
    Cardiovascular Pharmacology Division, ISF College of Pharmacy, Moga 142001, Punjab, India
    Pharmacol Res 60:24-32. 2009
    ..In addition, the recently identified potential target sites involved in the pathogenesis of diabetic nephropathy have been delineated...
  31. doi request reprint Do resident renal mast cells play a role in the pathogenesis of diabetic nephropathy?
    Pitchai Balakumar
    Department of Physiology, Faculty of Medicine, University of Montreal, Succ Centre Ville, Montreal, QC, H3C 3J7, Canada
    Mol Cell Biochem 330:187-92. 2009
    ..Recent studies suggest the involvement of renal mast cell infiltration and degranulation in diabetic nephropathy. The present review focuses on the role of resident renal mast cells in diabetic nephropathy...
  32. doi request reprint Modulation of cardioprotective effect of ischemic pre- and postconditioning in the hyperhomocysteinemic rat heart
    Pitchai Balakumar
    Cardiovascular Pharmacology Division, ISF College of Pharmacy, Punjab, India
    Methods Find Exp Clin Pharmacol 31:71-9. 2009
    ....
  33. doi request reprint The novel role of fenofibrate in preventing nicotine- and sodium arsenite-induced vascular endothelial dysfunction in the rat
    Jagdeep Kaur
    Pharmacology Division, ISF College of Pharmacy, Moga, 142 001, Punjab, India
    Cardiovasc Toxicol 10:227-38. 2010
    ....
  34. doi request reprint The low dose combination of fenofibrate and rosiglitazone halts the progression of diabetes-induced experimental nephropathy
    Mandeep Kumar Arora
    Cardiovascular Pharmacology Division, ISF College of Pharmacy, Moga 142 001, Punjab, India
    Eur J Pharmacol 636:137-44. 2010
    ....
  35. doi request reprint The infarct size-limiting effect of ischemic postconditioning (IPOC) is suppressed in isolated hyperhomocysteinemic (Hhcy) rat hearts: the reasonable role of PKC-delta
    Ankur Rohilla
    Cardiovascular Pharmacology Division, ISF College of Pharmacy, Moga 142 001, Punjab, India
    Biomed Pharmacother 63:787-91. 2009
    ..The present study investigated the possible role of PKC-delta in Hhcy-induced suppression of myocardial infarct size-limiting effect of IPOC...
  36. ncbi request reprint Effect of bis (maltolato) oxovanadium (BMOV) in uric acid and sodium arsenite-induced vascular endothelial dysfunction in rats
    Seema Jindal
    Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, India
    Int J Cardiol 128:383-91. 2008
    ....
  37. ncbi request reprint Effect of mast cell stabilizers in hyperhomocysteinemia-induced cardiac hypertrophy in rats
    Amrit Pal Singh
    Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, India
    J Cardiovasc Pharmacol 51:596-604. 2008
    ..The present study has been designed to investigate the effect of sodium cromoglycate and ketotifen, mast cell stabilizers in hyperhomocysteinemia-induced cardiac hypertrophy in rats...
  38. ncbi request reprint PPAR ligands: are they potential agents for cardiovascular disorders?
    Pitchai Balakumar
    Cardiovascular Pharmacology Division, Department of Pharmaceutical Sciences and Drug Research, Punjabi University Patiala, Patiala, India
    Pharmacology 80:1-10. 2007
    ..The function of PPARdelta and its potential as a cardiovascular therapeutic target are currently under investigation. The present review focuses on the merits and limitations of PPAR agonists with regard to their use in CVD...
  39. ncbi request reprint Ameliorative effect of combination of fenofibrate and rosiglitazone in pressure overload-induced cardiac hypertrophy in rats
    Madhankumar Rose
    Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, India
    Pharmacology 80:177-84. 2007
    ..Thus, it may be concluded that dual activation of PPARalpha and PPARgamma may provide synergistic benefits in preventing the development of pathological cardiac hypertrophy...
  40. ncbi request reprint Resident cardiac mast cells: are they the major culprit in the pathogenesis of cardiac hypertrophy?
    Pitchai Balakumar
    ISF Institute of Pharmaceutical Sciences and Drug Research, Moga, Punjab, India
    Basic Clin Pharmacol Toxicol 102:5-9. 2008
    ..Moreover, recent studies suggest the involvement of mast cells in cardiac hypertrophy and heart failure. The present review focuses on the role of mast cells in the development of cardiac hypertrophy and heart failure...
  41. ncbi request reprint The possible role of caspase-3 in pathological and physiological cardiac hypertrophy in rats
    Pitchai Balakumar
    Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, India
    Basic Clin Pharmacol Toxicol 99:418-24. 2006
    ..However, caspase-3 may not be involved in chronic swimming test-induced physiological cardiac hypertrophy...
  42. ncbi request reprint Differential role of rho-kinase in pathological and physiological cardiac hypertrophy in rats
    Pitchai Balakumar
    Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala 147002, India
    Pharmacology 78:91-7. 2006
    ..These results have implicated Rho-kinase in PAAC-induced LV dysfunction and pathological cardiac hypertrophy. However, Rho-kinase may not be involved in CST-induced physiological cardiac hypertrophy...
  43. ncbi request reprint Rodent models of heart failure
    Pitchai Balakumar
    Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, India
    J Pharmacol Toxicol Methods 56:1-10. 2007
    ..However, all animal models used have advantages and limitations, and the issues determining transfer from preclinical to clinical require critical evaluation. The present review focuses upon rodent models of heart failure...